{"entity":{"id":"nct06643754","kind":"trial","name":"A Clinical Study of SHR-3276 for Injection in Patients With Advanced Malignant Tumors","aka":[],"tldr":"A phase 1/2 trial of SHR-3276 in advanced solid tumours, run by Suzhou Suncadia Biopharmaceuticals Co., Ltd., now recruiting.","summary":"A Clinical Study of SHR-3276 for Injection in Patients With Advanced Malignant Tumors is a phase 1/2 interventional study registered as NCT06643754 by Suzhou Suncadia Biopharmaceuticals Co., Ltd., with 115 participants planned, started 2024-12-10 and due to reach its primary completion in 2027-12-30. Interventions recorded: SHR-3276.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06643754","url":"https://clinicaltrials.gov/study/NCT06643754"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["hengrui"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06643754","phase":"1/2","setting":"A Phase I/II Clinical Study on the Safety, Tolerability, Pharmacokinetics, and Efficacy of SHR-3276 Injection in Patients With Advanced Malignant Tumors","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","enrolled":115,"outcomes":[]},"route":"/trials/nct06643754/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"company":[{"id":"hengrui","kind":"company","name":"Jiangsu Hengrui Pharmaceuticals","route":"/companies/hengrui/"}]}}